Stock Track | Senseonics Soars on Eversense 365 Launch, Q3 Results

Stock Track11-08

Shares of Senseonics Holdings, Inc. (NYSE: SENS) surged 8.71% on Tuesday, November 7, 2024, driven by the successful launch of its newly approved Eversense 365 continuous glucose monitoring (CGM) system for diabetes patients and its third-quarter 2024 financial results.

In the third quarter, Senseonics received FDA approval for Eversense 365, a long-term, implantable CGM system that can monitor glucose levels for up to 365 days. The company has begun commercialization of the product in partnership with Ascensia Diabetes Care, a subsidiary of PHC Holdings Corporation.

Senseonics reported total revenue of $4.3 million for the third quarter, with $2.4 million coming from the U.S. market. While total revenue declined year-over-year due to the transition from its previous Eversense E3 system to Eversense 365, the company recorded a one-time charge of $4.8 million related to this transition. As a result, Senseonics reported a net loss of $24 million for the quarter, compared to a net loss of $24.1 million in the same period last year.

Looking ahead, Senseonics expects full-year 2024 global net revenue to be approximately $22 million, driven by the initial demand for Eversense 365 and the launch of a collaboration with the Mercy health system. The company anticipates more than doubling U.S. new patient starts and increasing its global installed base by approximately 50% in 2024 compared to 2023.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1109194209?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 05:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109194209","market":"us","top_or_hot":-1,"title":"Stock Track | Senseonics Soars on Eversense 365 Launch, Q3 Results","media":"Stock Track","content":"<p>Shares of Senseonics Holdings, Inc. (NYSE: SENS) surged 8.71% on Tuesday, November 7, 2024, driven by the successful launch of its newly approved Eversense 365 continuous glucose monitoring (CGM) system for diabetes patients and its third-quarter 2024 financial results.</p>\n\n<p>In the third quarter, Senseonics received FDA approval for Eversense 365, a long-term, implantable CGM system that can monitor glucose levels for up to 365 days. The company has begun commercialization of the product in partnership with Ascensia Diabetes Care, a subsidiary of PHC Holdings Corporation.</p>\n\n<p>Senseonics reported total revenue of $4.3 million for the third quarter, with $2.4 million coming from the U.S. market. While total revenue declined year-over-year due to the transition from its previous Eversense E3 system to Eversense 365, the company recorded a one-time charge of $4.8 million related to this transition. As a result, Senseonics reported a net loss of $24 million for the quarter, compared to a net loss of $24.1 million in the same period last year.</p>\n\n<p>Looking ahead, Senseonics expects full-year 2024 global net revenue to be approximately $22 million, driven by the initial demand for Eversense 365 and the launch of a collaboration with the Mercy health system. The company anticipates more than doubling U.S. new patient starts and increasing its global installed base by approximately 50% in 2024 compared to 2023.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Senseonics Soars on Eversense 365 Launch, Q3 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Senseonics Soars on Eversense 365 Launch, Q3 Results\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-08 05:37 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Senseonics Holdings, Inc. (NYSE: SENS) surged 8.71% on Tuesday, November 7, 2024, driven by the successful launch of its newly approved Eversense 365 continuous glucose monitoring (CGM) ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SENS","symbol_name":"Senseonics Holdings,Inc.","start_time":0,"source_url":"","article_id":"1109194209","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109194209","pubTimestamp":1731015429,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Senseonics Holdings, Inc.  surged 8.71% on Tuesday, November 7, 2024, driven by the successful launch of its newly approved Eversense 365 continuous glucose monitoring  system for diabetes patients and its third-quarter 2024 financial results.In the third quarter, Senseonics received FDA approval for Eversense 365, a long-term, implantable CGM system that can monitor glucose levels for up to 365 days. The company has begun commercialization of the product in partnership with Ascensia D","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SENS":"Senseonics Holdings,Inc."},"translate_title":"股票赛道Senseonics因Eversense 365发布和第三季度业绩而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SENS":1},"content_text":"Shares of Senseonics Holdings, Inc. (NYSE: SENS) surged 8.71% on Tuesday, November 7, 2024, driven by the successful launch of its newly approved Eversense 365 continuous glucose monitoring (CGM) system for diabetes patients and its third-quarter 2024 financial results.\nIn the third quarter, Senseonics received FDA approval for Eversense 365, a long-term, implantable CGM system that can monitor glucose levels for up to 365 days. The company has begun commercialization of the product in partnership with Ascensia Diabetes Care, a subsidiary of PHC Holdings Corporation.\nSenseonics reported total revenue of $4.3 million for the third quarter, with $2.4 million coming from the U.S. market. While total revenue declined year-over-year due to the transition from its previous Eversense E3 system to Eversense 365, the company recorded a one-time charge of $4.8 million related to this transition. As a result, Senseonics reported a net loss of $24 million for the quarter, compared to a net loss of $24.1 million in the same period last year.\nLooking ahead, Senseonics expects full-year 2024 global net revenue to be approximately $22 million, driven by the initial demand for Eversense 365 and the launch of a collaboration with the Mercy health system. The company anticipates more than doubling U.S. new patient starts and increasing its global installed base by approximately 50% in 2024 compared to 2023.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1109194209"}